Robert E. Geertsma

4.3k total citations · 2 hit papers
30 papers, 3.2k citations indexed

About

Robert E. Geertsma is a scholar working on Materials Chemistry, Biomaterials and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Robert E. Geertsma has authored 30 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Materials Chemistry, 5 papers in Biomaterials and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Robert E. Geertsma's work include Nanoparticles: synthesis and applications (9 papers), Nanoparticle-Based Drug Delivery (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Robert E. Geertsma is often cited by papers focused on Nanoparticles: synthesis and applications (9 papers), Nanoparticle-Based Drug Delivery (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Robert E. Geertsma collaborates with scholars based in Netherlands, Switzerland and United Kingdom. Robert E. Geertsma's co-authors include Wim H. de Jong, Adriënne J.A.M. Sips, Werner I. Hagens, Petra Krystek, Agnes G. Oomen, Evelyn H. W. Heugens, Dik van de Meent, B Roszek, S. Wijnhoven and Maaike van Zijverden and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biomaterials and International Journal of Molecular Sciences.

In The Last Decade

Robert E. Geertsma

29 papers receiving 3.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Particle size-dependent organ distribution of gold nanoparticles after intravenous administration

2008 1.3k citations Wim H. de Jong, Werner I. Hagens et al. Biomaterials profile →
Nano-silver – a review of available data and knowledge gaps in human and environmental risk assessment

2009 1.0k citations S. Wijnhoven, Willie J.G.M. Peijnenburg et al. Nanotoxicology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert E. Geertsma	1.9k	991	814	482	458	30	3.2k
Werner I. Hagens	1.9k 1.0×	930 0.9×	772 0.9×	471 1.0×	472 1.0×	11	3.3k
Petra Krystek	1.5k 0.8×	799 0.8×	776 1.0×	814 1.7×	413 0.9×	29	3.0k
Georgios Pyrgiotakis	2.7k 1.4×	1.3k 1.3×	960 1.2×	610 1.3×	412 0.9×	60	5.2k
Salman Alrokayan	2.3k 1.2×	1.3k 1.3×	748 0.9×	401 0.8×	835 1.8×	184	4.6k
Richard C. Murdock	2.3k 1.2×	1.3k 1.3×	513 0.6×	567 1.2×	366 0.8×	21	3.4k
Alan Casey	1.6k 0.8×	1.2k 1.2×	402 0.5×	308 0.6×	628 1.4×	71	3.5k
Jens Lipka	1.1k 0.6×	619 0.6×	773 0.9×	544 1.1×	448 1.0×	13	2.4k
Stephanie Hirn	1.1k 0.6×	644 0.6×	749 0.9×	499 1.0×	403 0.9×	26	2.3k
Mohd Javed Akhtar	3.2k 1.7×	1.5k 1.6×	866 1.1×	771 1.6×	761 1.7×	112	5.2k
Ru Bai	2.1k 1.1×	1.8k 1.8×	1.1k 1.3×	555 1.2×	816 1.8×	124	4.8k

Countries citing papers authored by Robert E. Geertsma

Since Specialization

Citations

This map shows the geographic impact of Robert E. Geertsma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Geertsma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Geertsma more than expected).

Fields of papers citing papers by Robert E. Geertsma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Geertsma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Geertsma. The network helps show where Robert E. Geertsma may publish in the future.

Co-authorship network of co-authors of Robert E. Geertsma

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Geertsma. A scholar is included among the top collaborators of Robert E. Geertsma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Geertsma. Robert E. Geertsma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Melvin, Tom, Anne Lübbeke, Robert E. Geertsma, et al.. (2024). Safety notices and registry outlier data measure different aspects of safety and performance of total knee implants: a comparative study of safety notices and register outliers. Acta Orthopaedica. 95. 667–676.

Jennen, Danyel, Marcel van Herwijnen, Marlon J. Jetten, et al.. (2022). Transcriptomic Analysis in Human 3D Skin Model Injected with Resorbable Hyaluronic Acid Fillers Reveals Foreign Body Response. International Journal of Molecular Sciences. 23(21). 13046–13046. 6 indexed citations

Jong, Wim H. de, Danyel Jennen, Peter H. J. Keizers, et al.. (2022). Evaluation of Adverse Effects of Resorbable Hyaluronic Acid Fillers: Determination of Macrophage Responses. International Journal of Molecular Sciences. 23(13). 7275–7275. 6 indexed citations

Jong, Wim H. de, Robert E. Geertsma, & Gerrit Borchard. (2022). Regulatory safety evaluation of nanomedical products: key issues to refine. Drug Delivery and Translational Research. 12(9). 2042–2047. 19 indexed citations

Halamoda‐Kenzaoui, Blanka, Robert E. Geertsma, Adriele Prina‐Mello, et al.. (2022). Future perspectives for advancing regulatory science of nanotechnology-enabled health products. Drug Delivery and Translational Research. 12(9). 2145–2156. 14 indexed citations

Zabeo, Alex, Lisa Pizzol, Fanny Caputo, et al.. (2022). A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS. Drug Delivery and Translational Research. 12(9). 2101–2113. 3 indexed citations

Park, Margriet V.D.Z., Wim H. de Jong, Jan Willem van der Laan, et al.. (2020). Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 12(5). e1633–e1633. 16 indexed citations

Brand, Walter, C.W. Noorlander, Wim de Jong, et al.. (2017). Nanomedicinal products: a survey on specific toxicity and side effects. International Journal of Nanomedicine. Volume 12. 6107–6129. 45 indexed citations

Park, Margriet V.D.Z., et al.. (2016). A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. International Journal of Nanomedicine. 11. 2935–2935. 46 indexed citations

10.

Doggen, Carine J.M., et al.. (2015). Results of a survey among GP practices on how they manage patient safety aspects related to point-of-care testing in every day practice. BMC Family Practice. 16(1). 9–9. 9 indexed citations

11.

Geertsma, Robert E., Liesbeth Geraets, Wim Mennes, et al.. (2014). Bisphenol A : Part 1. Facts and figures on human and environmental health issues and regulatory perspectives. Rivm Repository (Netherlands National Institute for Public Health and the Environment). 2 indexed citations

12.

Ossebaard, Hans C., et al.. (2013). Risks related to the use of eHealth technologies : An exploratory study. American Journal of Translational Research. 12(10). 6827–6840. 7 indexed citations

13.

Geertsma, Robert E., et al.. (2013). MEDICAL TECHNOLOGY AT HOME: SAFETY-RELATED ITEMS IN TECHNICAL DOCUMENTATION. International Journal of Technology Assessment in Health Care. 29(1). 20–26. 9 indexed citations

14.

Geertsma, Robert E., et al.. (2013). Clinical data on injectable tissue fillers: a review. Expert Review of Medical Devices. 10(6). 835–853. 23 indexed citations

15.

Bleeker, Eric A.J., Wim H. de Jong, Robert E. Geertsma, et al.. (2012). Considerations on the EU definition of a nanomaterial: Science to support policy making. Regulatory Toxicology and Pharmacology. 65(1). 119–125. 126 indexed citations

16.

Bleeker, Eric A.J., Flemming R. Cassee, Robert E. Geertsma, et al.. (2012). Interpretation and implications of the European Commission's definition on nanomaterials. UvA-DARE (University of Amsterdam). 3 indexed citations

17.

Oomen, Agnes G., Petra Krystek, Arianne M. Neigh, et al.. (2010). The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials. 31(32). 8350–8361. 411 indexed citations

18.

Wijnhoven, S., Willie J.G.M. Peijnenburg, Carla Herberts, et al.. (2009). Nano-silver – a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology. 3(2). 109–138. 1022 indexed citations breakdown →

19.

Jong, Wim H. de, et al.. (2008). Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 29(12). 1912–1919. 1264 indexed citations breakdown →

20.

Jong, Wim H. de, et al.. (2002). Medical devices manufactured from latex: European regulatory initiatives. Methods. 27(1). 93–98. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact